Medical Condition News

RSS

Researchers dispute study findings that show greater incidence of surgery for children with CD

A new multi-center study of 854 children with Crohn's disease shows a 5-year cumulative risk of bowel surgery is significantly lower than reported in recent studies. The findings of the study, led by Hasbro Children's Hospital, also indicate that children diagnosed between ages 13 and 16 had an increased risk of bowel surgery, and that a common treatment that begins at diagnosis, immunomodulator therapy, did not alter the risk of surgery.

2 Sep 2010

Agent Orange cases expanded; Added costs raise fiscal concerns

Hundreds of thousands of Vietnam War veterans are receiving disability compensation for diseases normally associated with aging - not combat - because of the possibility of a link Agent Orange exposure. The diseases in question range from diabetes, for which 270,000 veterans receive Agent Orange-related checks, to erectile dysfunction.

2 Sep 2010

Saint Barnabas Medical Center installs ZOLL's AutoPulse Non-Invasive Cardiac Support Pump

ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that Saint Barnabas Medical Center, one of the largest non-profit, non-sectarian hospitals in New Jersey, has installed the AutoPulse® Non-Invasive Cardiac Support Pump for resuscitative capabilities in the hospital's emergency department.

2 Sep 2010

XARELTO achieves net clinical benefit in treatment of patients with DVT

Bayer HealthCare Pharmaceuticals today announced that XARELTO (rivaroxaban), a novel anti-clotting therapy, achieved improvement in net clinical benefit in a study looking at treatment of patients with deep vein thrombosis. DVT is the formation of a blood clot in a deep vein, usually in the legs, that partially or totally blocks the flow of blood.

2 Sep 2010

First Phase I/II clinical trial to test MK-0752 in patients with advanced pancreatic cancer

Cancer Research UK's Drug Development Office has launched a clinical trial* to test an experimental drug in patients with advanced (Stage IV) pancreatic cancer - one of the most difficult cancers to treat.

2 Sep 2010

Cannabis Science issues statement on marijuana study for post-surgery neuropathic pain

Cannabis Science, Inc., a pioneering U.S. biotech company developing pharmaceutical cannabis products, has issued a statement regarding a Canadian study on marijuana and intractable post-traumatic or post-surgery neuropathic pain that did not respond to conventional treatment.

2 Sep 2010

Chronic insomnia with objectively measured short sleep duration associated with increased mortality in men

A study in the Sept. 1 issue of the journal SLEEP found an elevated risk of death in men with a complaint of chronic insomnia and an objectively measured short sleep duration. The results suggest that public health policy should emphasize the diagnosis and appropriate treatment of chronic insomnia.

2 Sep 2010

Study links community violence with asthma hospitalizations, emergency department visits

Patients with asthma who are exposed to violence in their community are at an increased risk for an asthma-related hospitalization and emergency room visits for asthma or any cause, according to new research from the University Of Pennsylvania School of Medicine. Exposure to community violence has been linked to more symptoms in pediatric asthma patients; however the new research adds to this finding with a longitudinal study showing a connection in an adult population and more than symptoms - actual emergency department visits and hospitalizations.

2 Sep 2010

More patients research their own diseases, seek to manage chronic conditions

News outlets report on how the delivery of health care is being changed by empowered patients.

2 Sep 2010

BRINAVESS IV granted marketing approval in EU for conversion of recent onset AF to sinus rhythm

MSD and Cardiome Pharma Corp. today announced that the intravenous (IV) formulation of BRINAVESS™ (vernakalant) has been granted marketing approval in the European Union (EU), Iceland and Norway for the conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults.

2 Sep 2010

Researcher awarded $1.8M grant to investigate sex differences in anxiety

Anxiety disorders afflict women twice as often as men, but estrogen might not be the reason. Testosterone, though, could be. That is one of the preliminary findings in the lab of Florida State University researcher Mohamed Kabbaj, associate professor in the College of Medicine. He recently was awarded a five-year, $1.8 million grant from the National Institute of Mental Health to investigate the sex differences in anxiety.

2 Sep 2010

Mipomersen Phase 3 trial in heFH meets primary, secondary and tertiary endpoints

Genzyme Corp. and Isis Pharmaceuticals Inc. announced that data from the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) were presented today at the European Society of Cardiology's Congress 2010 in Stockholm, Sweden. The study met its primary endpoint with a 28 percent reduction in LDL-cholesterol, compared with an increase of 5 percent for placebo (p<0.001). The trial also met all of its secondary and tertiary endpoints.

2 Sep 2010

TGen researchers use RNAi-based screening to study Ewing's sarcoma

The first study of Ewing's sarcoma that screened hundreds of genes based on how they affect cell growth has identified two potential anti-cancer drug targets, according to a scientific paper by the Translational Genomics Research Institute published this month in the journal Molecular Cancer.

2 Sep 2010

Cellerant Therapeutics signs contract with BARDA to develop CLT-008 therapy for ARS

Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced today that it has signed a contract valued at up to $153 million over five years with the Biomedical Advanced Research and Development Authority (BARDA) in the Office of the Assistant Secretary for Preparedness and Response of the Department of Health and Human Services, to develop CLT-008, a cellular therapy for the treatment of Acute Radiation Syndrome (ARS).

2 Sep 2010

Increased physical activity can reduce cardiovascular risk in children from lower socio-educational background

A year-long study into the effects of increased physical activity at school has shown that children's fitness levels and body composition do improve with daily participation in sport - and particularly so for children from deprived backgrounds. Obesity among children and young people continues to rise across Europe and brings with it the very real risk of increased blood pressure, higher blood-fat values and impaired glucose tolerance.

2 Sep 2010

ThromboGenics second microplasmin Phase III trial for non-surgical treatment of VMA meets primary endpoint

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer announces that its second Phase III trial evaluating microplasmin for the non-surgical treatment of vitreomacular adhesion (VMA) has met its primary endpoint.

2 Sep 2010

Multispectral imaging of ocular fundus using new LED Illumination system

A new imaging system using six different wavelengths to illuminate the interior of the eyeball (ocular fundus) may pave the way for doctors to easily screen patients for common diseases of the eye, such as age-related macular degeneration and diabetic retinopathy. The system is described in the journal Review of Scientific Instruments, which is published by the American Institute of Physics.

2 Sep 2010

Pfizer enters agreement to acquire FoldRx Pharmaceuticals

Pfizer Inc. and FoldRx Pharmaceuticals, Inc., a privately held drug discovery and clinical development company, today announced that they have entered into an agreement under which Pfizer will acquire FoldRx.

2 Sep 2010

Blood pressure treatment may prevent end-stage kidney disease in some patients: Study

Intensively treating hypertension in some African Americans with kidney disease by pushing blood pressure well below the current recommended goal may significantly decrease the number who lose kidney function and require dialysis, suggests a Johns Hopkins-led study publishing in the New England Journal of Medicine Thursday.

2 Sep 2010

Estradiol prevents vascular permeability following hemorrhagic shock: Study

A study published in the September 2010 issue of SHOCK by Dr. Ed W. Childs and colleagues at Scott & White Healthcare looks at how female versus male rats fared after suffering a trauma and subsequent hemorrhagic shock who were given Estradiol (estrogen). In the study, the Estradiol prevented vascular permeability following hemorrhagic shock.

2 Sep 2010

Medical Condition News

Researchers dispute study findings that show greater incidence of surgery for children with CD

Agent Orange cases expanded; Added costs raise fiscal concerns

Saint Barnabas Medical Center installs ZOLL's AutoPulse Non-Invasive Cardiac Support Pump

XARELTO achieves net clinical benefit in treatment of patients with DVT

First Phase I/II clinical trial to test MK-0752 in patients with advanced pancreatic cancer

Cannabis Science issues statement on marijuana study for post-surgery neuropathic pain

Chronic insomnia with objectively measured short sleep duration associated with increased mortality in men

Study links community violence with asthma hospitalizations, emergency department visits

More patients research their own diseases, seek to manage chronic conditions

BRINAVESS IV granted marketing approval in EU for conversion of recent onset AF to sinus rhythm

Researcher awarded $1.8M grant to investigate sex differences in anxiety

Mipomersen Phase 3 trial in heFH meets primary, secondary and tertiary endpoints

TGen researchers use RNAi-based screening to study Ewing's sarcoma

Cellerant Therapeutics signs contract with BARDA to develop CLT-008 therapy for ARS

Increased physical activity can reduce cardiovascular risk in children from lower socio-educational background

ThromboGenics second microplasmin Phase III trial for non-surgical treatment of VMA meets primary endpoint

Multispectral imaging of ocular fundus using new LED Illumination system

Pfizer enters agreement to acquire FoldRx Pharmaceuticals

Blood pressure treatment may prevent end-stage kidney disease in some patients: Study

Estradiol prevents vascular permeability following hemorrhagic shock: Study

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News